CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
新型非病毒体内 CAR-T 疗法：2025 ASH 年会最新进展
英文原题：Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting.
查看英文原题
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体 (CAR)-T 细胞疗法领域正在经历从复杂的离体生产到直接体内生成 CAR-T 细胞的范式转变。这一创新方法利用非病毒递送平台原位重编程患者自身的免疫细胞，有望克服成本、可扩展性和可及性等关键障碍。2025 年美国血液学会 (ASH) 年会展示了一系列非病毒技术的突破性临床前数据，包括先进的脂质纳米颗粒 (LNPs)、病毒样颗粒 (VLPs) 和聚合物纳米颗粒。本通讯总结了这些平台的最新报告，强调其彻底改变自身免疫性疾病和血液系统恶性肿瘤治疗的潜力。
展开英文摘要原文
The field of chimeric antigen receptor (CAR)-T cell therapy is undergoing a paradigm shift from complex ex vivo manufacturing to direct in vivo generation of CAR-T cells. This innovative approach leverages non-viral delivery platforms to reprogram a patient's own immune cells in situ, promising to overcome critical barriers of cost, scalability, and accessibility.
The 2025 American Society of Hematology (ASH) Annual Meeting served as a showcase for groundbreaking preclinical data across a diverse array of non-viral technologies, including advanced lipid nanoparticles (LNPs), virus-like particles (VLPs), and polymeric nanoparticles. This correspondence summarizes the latest reports on these platforms, highlighting their potential to revolutionize the treatment of both autoimmune diseases and hematological malignancies.
论文信息
- 作者
- Xue B、Liu Y、Liang A、Zhang W
- 第一作者单位
- Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China.China
- 通讯作者单位
- Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, 200065, China. zhangwenjun@tongji.edu.cn.China
- 文献类型
- 读者来信
- 期刊
- Experimental hematology & oncology2026 Mar 19
- 原文标识
- PubMed 41857667 · DOI 10.1186/s40164-026-00765-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →